laventatug tivedotin

An antibody-drug conjugate (ADC) composed of laventatug, a humanized monoclonal antibody directed against solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) that is conjugated, via a linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and binding to LIV-1-positive tumor cells, laventatug tivedotin enters the tumor cell lysosome through endocytosis, and releases MMAE. MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a multi-pass transmembrane protein and zinc transporter, is expressed in several types of solid tumors and plays a key role in tumor cell progression, proliferation and metastasis. The conjugation method and linkage system prevent MMAE from separating from the antibody during circulation, thereby limiting off target toxicity.